CAMBRIDGE, Mass — Today following the FDA’s approval of Aduhelm (aducanumab) for Alzheimer’s disease, Biogen announced it it working with CVS Health and the intention to enter into a value-based contract with Cigna.

Starting in September, CVS will make cognitive screenings available through its Project Health program, which aims to narrow care disparities. The program will begin in Atlanta, Boston/Providence, Charlotte, Charleston/Columbia, Chicago, Dallas/Fort Worth, Detroit, Houston, Jackson/Memphis, Los Angeles, Miami, New York City, Philadelphia, and Washington, DC.

In addition, Biogen plans to work with the National Association of Free and Charitable Clinics to develop a program program that supports brain health and culturally competent Alzheimer’s disease education for patients and healthcare providers.

Biogen and Cigna also plan on entering a valued-based contract that will base payments for the medication based on how well a patient responds to it.